INmune Bio Q3 net loss $12.1M; Phase 2 Alzheimer's trial fully enrolled; top-line data Q2 2025

Inmune Bio, Inc.

2024-Q3 EPS reported -$1.71 revenue$14,000

Net loss $12.1M vs $8.6M Q3 2023; R&D expenses $10.1M (up from $6.0M).
Cash and equivalents $33.6M as of Sept 30; raised $13.0M in securities purchase agreement.
Phase 2 AD trial (XPro) fully enrolled with 201 planned patients; top-line data expected Q2 2025.
INKmune in prostate cancer trial showed safety and NK cell activity in first cohort; highest dose cohort dosing began.
Received $2.5M R&D rebate from Australia in July.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.